Influenza Test Kits: Antigen vs Molecular Detection

Influenza (“flu”) test kits generally fall into two categories: rapid antigen tests (immunoassays) and molecular (nucleic acid) tests. Both use patient respiratory specimens (usually nasal or throat swabs). Rapid antigen kits detect the virus’s proteins, while molecular kits detect viral genetic material. Rapid tests (also known as Rapid Influenza Diagnostic Tests, RIDTs) are lateral-flow or similar immunoassays that identify influenza A or B viral nucleoprotein antigens in the specimen. Molecular tests (typically RT-PCR or other NAATs) amplify and detect influenza virus RNA with very high sensitivity and specificity. The reference standard for confirming influenza infection is RT-PCR or viral culture, but RIDTs can provide quicker results at the point-of-care.

Rapid Antigen (RIDT) Kits (Immunoassays)

• Principle: These kits use antibody-based immunoassays to capture influenza virus antigens. The device contains antibodies against influenza A and B nucleoproteins, often on a nitrocellulose strip. In a typical lateral-flow cassette, the sample (after mixing with buffer) flows by capillary action along the strip. If influenza antigens are present, they bind conjugated (labeled) anti-influenza antibodies and are “sandwiched” by capture antibodies on a test line. This produces a visible colored line (for Influenza A or B) on the strip. A separate control line must appear in each test to confirm the assay worked properly. Most RIDTs can distinguish A vs B, but they cannot determine influenza A subtypes (e.g. H1 vs H3).

• Procedure: A clinician (or patient, in home tests) collects a nasal or nasopharyngeal swab and inserts it into a vial of assay buffer. A few drops of this solution are placed in the test cassette. Over ~10–15 minutes the fluid migrates along the strip. A colored test line appears if the viral antigen was captured, and a control line should always appear if the test is valid.

• Time & Use: Results are ready in roughly 10–15 minutes (often under 30 minutes). Because of their speed and simplicity, many RIDTs are CLIA-waived and approved for point-of-care or home use. They require no specialized equipment, only the test device and reagent.

• Accuracy: RIDTs are highly specific (≈90–95%) so a positive result usually means true influenza infection. However, sensitivity is limited – CDC notes typical sensitivities of ~50–70% (range ~10–80% in studies). In practice this means false negatives are common, especially when flu prevalence is high. Thus a negative RIDT does not reliably rule out influenza; PCR confirmation is often recommended if clinical suspicion is strong. Negative results should be interpreted with caution during peak flu season.

Molecular (NAAT/PCR) Kits

• Principle: Molecular assays detect influenza virus RNA. In RT-PCR (reverse transcription polymerase chain reaction) tests, the extracted viral RNA from the specimen is converted into DNA and amplified using influenza-specific primers and probes. The probes (often fluorescent) signal when target sequences are present. This amplification makes the tests extremely sensitive, able to detect very small amounts of virus. CDC reports FDA-cleared rapid molecular kits have ~90–95% sensitivity and similarly high specificity.

• Procedure: The respiratory swab is typically placed in transport medium and sent to a lab (or loaded into a point-of-care instrument). The instrument automatically (or via technician) lyses the virus, extracts RNA, and runs RT-PCR cycles. Many commercial kits target conserved influenza genes (e.g. matrix protein or hemagglutinin segments). Some platforms provide multiplex panels (simultaneously testing for flu A, flu B, RSV, SARS-CoV-2, etc.) using separate detection channels.

• Time & Use: Laboratory RT-PCR assays usually take on the order of 1–4 hours for results (plus sample transport time). Newer point-of-care NAAT systems (e.g. Abbott ID NOW, Cepheid GeneXpert, Roche Liat) can yield results in as little as 15–30 minutes. These rapid molecular kits are also sometimes CLIA-waived. Overall, molecular tests require more equipment than RIDTs but offer much higher sensitivity. Because of this, negative molecular test results are quite reliable.

• Accuracy: Molecular kits are far more sensitive than antigen tests. CDC notes >90–95% sensitivity for FDA-cleared molecular influenza assays. They are the gold standard for detection. Importantly, many molecular kits can subtype influenza A (e.g. distinguishing H1N1 vs H3N2) and quantify viral load if needed (in research/epidemiology contexts).

Summary

In practice, rapid antigen kits work by detecting viral proteins via antibody “sandwich” or immunofluorescence methods on a test strip, yielding a quick yes/no result with distinguishable A/B lines. Molecular kits work by amplifying and detecting viral RNA (e.g. RT-PCR), which takes longer but is much more sensitive. Both use samples from the patient’s respiratory tract. Positive antigen or PCR results confirm influenza virus, but only PCR can reliably rule it out. (Viral culture is another laboratory method, but it is slow and largely used only for specialized labs

Top Influenza Test Kit Brands

Healthcare providers use both rapid antigen tests (immunoassays) and rapid molecular tests for influenza. Major manufacturers and their flagship products include Abbott, Quidel (Ortho), BD, Roche, Cepheid, LumiraDx, and others. Below we highlight top brands and key differences between their influenza test kits.

• Abbott – Provides both antigen and molecular POC kits. BinaxNOW™ Influenza A & B Card is a simple lateral-flow antigen test card (CLIA-waived) for nasal swabs, giving results in ~15 minutes. Its reported sensitivity is moderate (roughly 70–89% for Flu A and 50–69% for Flu B). By contrast, Abbott’s ID NOW Influenza A & B 2 is a molecular (isothermal NAAT) test used on the portable ID NOW instrument. ID NOW runs in ~13–15 min (including a ~3-min warm-up) and can even call positives in 2–5 min (early-call mode). ID NOW’s sensitivity is high (≈93–97% for Flu A/B) greatly exceeding the antigen test. In summary, Abbott’s BinaxNOW is fast and simple (no instrument) but less sensitive, whereas ID NOW is slightly slower, needs a dedicated reader, but yields much more accurate results.

• Quidel (QuidelOrtho) – Also offers both antigen and semi-automated tests. The QuickVue Influenza A+B test is a traditional lateral-flow strip (visual color read) requiring no instrument, with ~10–15 min to result. Its performance is similar to other color-based RIDTs. Quidel’s Sofia® Influenza A+B FIA is a fluorescent lateral-flow immunoassay run on the Sofia/Sofia 2 analyzer. Sofia’s instrument reads the strip automatically and delivers results in as little as 3–15 minutes. Sofia’s reported sensitivity is higher – in one study Sofia detected ~94.5% of Flu A and 91.7% of Flu B cases, whereas conventional lateral-flow tests (like QuickVue) are typically less sensitive. (For example, BD’s Veritor antigen test in the same study detected ~87.7% A and 81.7% B). In short, Quidel’s Sofia system trades complexity (needs a reader) for improved sensitivity, while QuickVue is instrument-free but has only moderate sensitivity (like most color strip tests).

• BD (Becton Dickinson) – Known for the Veritor System Flu A+B. This is a lateral-flow immunofluorescence assay requiring the small BD Veritor analyzer. It runs in ≤15 min and is CLIA-waived. BD Veritor’s sensitivity is comparable to other instrument-read antigen tests. In the cited study, Veritor detected about 87–88% of Flu A cases and ~81–82% of Flu B. So again, BD’s test is faster and more user-friendly than lab PCR, but less sensitive than molecular assays. (BD also has Combo tests for Flu+RSV and had earlier rapid antigen devices.)

• Roche – The major influenza test from Roche is the cobas® Liat system. The cobas Liat Influenza A/B assay is a fully integrated RT-PCR cartridge. It delivers results in ~20 minutes (“sample-to-answer”), with hands-on prep <5 min. Its analytic sensitivity is very high – in one pediatric study Liat detected 100% of Flu A positives and 94.4% of Flu B positives. (All molecular assays had >97% sensitivity for Flu A). Roche also markets influenza antigen tests (via partnership with SD Biosensor), but the Liat PCR is its flagship flu assay – it requires the desktop Liat instrument but gives near-PCR accuracy at point-of-care speed.

• Cepheid – Offers the Xpert® Xpress Flu (and Flu/RSV) test on the GeneXpert (Xpress) system. This is a cartridge-based RT-PCR (multiplex) with ~30 min run time. Like Liat, it is CLIA-waived and point-of-care. Its sensitivity is similarly high: in the same comparison, Xpert detected 100% of Flu A and ~91.7% of Flu B. Thus Cepheid Xpert and Roche Liat both deliver rapid, highly accurate molecular diagnostics. The key difference is runtime (Xpert ~30 min vs Liat ~20 min); both require instruments and cost more than simple antigen kits, but provide near-perfect detection (as recommended by IDSA guidelines for outpatient flu testing).

• LumiraDx – A newer POC platform providing combined SARS-CoV-2 and Flu A/B antigen testing. The LumiraDx SARS-CoV-2 & Flu A/B Test uses microfluidic immunofluorescence on a handheld reader. It processes a single nasal swab for all three targets in about 12 minutes. This test elevates antigen performance; a study found it achieved ~83% positive agreement for Flu A and 80% for Flu B compared with PCR with ≥95% negative agreement. In practice, LumiraDx sits between strip tests and lab PCR: it’s fast and portable (like other POC tests) but more sensitive than typical lateral flow (though still not as high as PCR).

• Other systems (multiplex lab platforms): Several companies market high-throughput or multiplex panels that include influenza. For example, BioFire FilmArray Respiratory Panel (bioMérieux) runs ~1 hr of real-time PCR to detect 20+ pathogens (including Flu A/B, RSV, etc.). Hologic Panther Fusion and Qiagen QIAstat-Dx are also multiplex PCR systems (for lab use or POC in some versions) that can test for flu alongside other viruses. These assays give very high accuracy but require instruments and are used in central labs or advanced clinics rather than home use.

In summary: Most major test brands come in two flavors: antigen (immunoassay) and molecular (NAAT) kits. Antigen “rapid” kits (Abbott BinaxNOW, Quidel Sofia/QuickVue, BD Veritor, LumiraDx, etc.) are fastest and simplest (often CLIA-waived) but only moderately sensitive. Among them, instrument-read assays (Sofia, Veritor, LumiraDx) tend to outperform naked-eye lateral flows (BinaxNOW, QuickVue). Molecular POC kits (Abbott ID NOW, Roche Liat, Cepheid Xpert) require small machines but give much higher accuracy – they detect almost all true flu cases and rule out infection reliably. Finally, large multiplex systems (bioMérieux, Hologic, etc.) detect flu within broader pathogen panels, useful in hospitals. Each brand’s kit differs in technology, runtime, throughput, and sensitivity, so clinicians choose based on setting and need (speed vs. accuracy vs. range of pathogens).

How to Use an Influenza (Flu) Test Kit

Disclaimer: I am not a medical professional. This answer provides general guidance based on typical kit instructions and public health information. Always read and follow the specific instructions provided with your test kit, and consult a healthcare provider if you have concerns or symptoms.

Influenza (flu) rapid test kits (usually lateral-flow immunoassays) detect viral proteins from a respiratory sample and give results in ~10–15 minutes. Many kits check separately for influenza A and B. Using a kit generally involves these steps:

1. Prepare for Testing

• Read all instructions first. Ensure the kit is authorized or cleared by your health regulator. Check the expiration date. Only use the test kit within its specified temperature range. For best results, bring the kit components to room temperature (about 15–30 °C) before starting. (Some manufacturers explicitly instruct opening the sealed pouch and equilibrating the test device and buffer to room temp.)
• Gather materials. A typical kit includes: test cassette(s), a buffer or extraction solution in a small tube, a sealed swab for sample collection, and a dropper cap or nozzle. Clear a clean, level workspace. Wash your hands thoroughly before handling the kit. Wear gloves if recommended or needed.

2. Collect the Respiratory Sample

• Nasal or throat swab as directed: Different kits allow different sample types. Many rapid flu tests use nasal or nasopharyngeal (NP) swabs; some allow a throat swab (or a combined nose+throat swab). Follow the kit’s instructions for which type to collect.
• Nasopharyngeal swab (for kits that require it): Insert the swab gently into one nostril, back and low (parallel to the palate, not upwards) until resistance is felt at the nasopharynx (roughly the distance from nostrils to outer ear). Rotate the swab 5–10 times and hold it in place for about 5–10 seconds to absorb mucus. (This is typically done one nostril at a time; you can reuse the same swab in the other nostril if needed.)
• Nasal (anterior) swab (common for home kits): If the kit specifies an anterior nasal swab, insert only the tip (usually 1–2 cm into the nostril) and rotate it against the inside of each nostril several times to collect mucus.
• Throat swab (if required): For kits that collect throat specimens, swab the back of the throat and tonsil areas (avoiding the tongue) firmly for a few seconds.
• After sampling: Place the swab into the extraction tube immediately (next step) to preserve the sample. Never reuse a swab or touch it to any other surface.

(These collection methods are consistent with CDC guidance: various respiratory specimens like swabs from the nose or throat are acceptable for flu tests, and one how-to guide advises inserting the swab straight back (not up) and rotating it several times).

3. Extract the Sample into the Buffer

Each kit has its own extraction solution (buffer). Perform exactly as instructed, typically as follows:

1. Add swab to buffer tube: Tear off the cap or foil seal of the buffer (extraction) tube. Insert the swab tip into the liquid.
2. Mix sample: Swirl or rotate the swab vigorously in the buffer. For example, one kit’s instructions say to rotate the swab about 10 times for ~15 seconds and press it against the tube wall to release antigen. This helps transfer virus particles from the swab into the liquid.
3. Remove the swab: While squeezing the tube walls, pull the swab out of the buffer and squeeze the tip against the tube sides to extract as much liquid as possible. Discard the swab properly (see Disposal below).
4. Cap and mix: Secure the dropper cap or nozzle on the tube. Gently flick or shake the tube a few times to mix the sample well with the buffer.

(Note: Some kits use slightly different terms or steps, but all involve transferring the specimen to the liquid. For example, instructions often emphasize mixing the swab in the tube and pressing out fluid, then sealing and shaking the tube.)

4. Transfer to the Test Device

• Place the test cassette on a flat surface. Open its foil pouch and lay the device flat.
• Apply sample: Use the dropper tip on the extraction tube to add the correct number of drops of liquid to the sample well(s) on the test cassette. Many kits specify 2–3 drops. For instance, one protocol directs “Add two drops of extracted specimen to each specimen well on the test card”. A tip: if fluid does not migrate along the strip within a minute, some instructions advise adding an extra drop.
• Start timing: Immediately start the timer once you’ve added the drops. Do not read results too early or too late. The typical read time is around 10–15 minutes. For example, one kit says to read the result at 10 minutes and that any result after 20 minutes is no longer valid. (Another CDC note: rapid tests “produce quick results in less than approximately 15 minutes”.)

5. Read and Interpret the Results

• Look for lines at the test “window.” The test cassette usually has a “control” line (C) and one or two “test” lines labeled for Influenza A and/or B. After the specified time (e.g. 10 minutes), observe where colored lines appear.

• Control line (C): A line should always appear at the C position if the test worked correctly. If no line appears at C, the test is invalid and you must repeat it with a new kit.

• Negative result: If you see only the control line (C) and no line at A or B, the result is negative (no flu A or B antigens detected).

• Positive result: If the control line plus one or more test lines appear, that indicates flu infection:

  • Flu A positive: Line at C and line at the A region (no line at B) suggests Influenza A.
  • Flu B positive: Line at C and line at the B region (no line at A) suggests Influenza B.
  • Both A & B positive: Lines at C, A, and B means antigens for both A and B were detected (this is less common).
  • (Any line, even a faint one, at A or B should be considered positive.)

  These interpretations match typical kit legends. For example, one manufacturer’s guide notes:

  • “Negative: One red line at C, and no lines at A or B”.
  • “Flu A positive: lines at C and A”;
  • “Flu B positive: lines at C and B”;
  • “Flu A&B positive: lines at C, A, and B”.
  • It further warns “No red line at C (even if lines appear at A or B) means the test is invalid”).

• Recording the result: Immediately note the result when the specified time is reached. Do not interpret the test before the minimum time (it may not have developed) and do not wait beyond the maximum time (false lines can appear).

6. After the Test – Disposal and Follow-up

• Dispose safely: Most kits advise disposing of the used swab, test strip, and other materials according to biohazard or local regulations. In practice, at home you should seal the used items (especially the swab) in a plastic bag and throw them in the trash. Wash your hands after handling used materials. (Clean any spills with disinfectant.)
• Consider next steps: Remember that rapid flu tests have moderate sensitivity. CDC notes that RIDTs (rapid influenza diagnostic tests) do not detect up to ~30–50% of true flu cases. In other words, a negative rapid test does not completely rule out influenza. If you have symptoms of flu (fever, aches, cough, etc.) and a negative test, or if you are in a high-risk group, consult a healthcare provider. They may recommend further testing (PCR) or empirical treatment. Conversely, a positive result suggests flu infection; follow CDC guidance on isolation or antiviral treatment as advised by your doctor.
• Storage: If you kept a spare kit, store it as directed (often at room temperature, not frozen).

Key Points and Precautions

• Always follow the specific kit’s instructions_for use carefully. Different brands may have slightly different steps or timing.
• Wear a mask or gloves if needed, and perform testing in a well-ventilated area if you suspect you are infectious.
• Do not reuse any component of the kit. Use a new swab and cassette for each test.
• Remember that these tests are meant to help screen for flu. They are FDA-approved or authorized for influenza A/B antigen detection, often alongside other tests (like COVID-19) in multiplex kits. They are designed to be used by healthcare providers or by laypersons at home (if the kit is authorized for home use). In all cases, results should be interpreted in the context of symptoms and possibly confirmed by a doctor if needed.
• Symptoms alone during flu season often suffice for a clinical diagnosis. Rapid tests can aid decision-making (e.g. prescribing antivirals) but CDC warns not to withhold treatment based on a negative rapid test if influenza is strongly suspected.

In summary: collect the sample as directed (usually with a nasal swab), immerse and mix it in the extraction buffer, apply the liquid to the test strip, and wait the specified time. Then read off the lines: control-only is negative, control+line(s) at A/B indicate which flu type is present. Dispose of kit parts safely and consult healthcare guidance for next steps.